Therapeutic potential of apelin and Elabela in cardiovascular disease - PubMed

Review

Therapeutic potential of apelin and Elabela in cardiovascular disease

Shenghan Gao et al. Biomed Pharmacother. 2023 Oct.

Free article

Abstract

Apelin and Elabela (Ela) are peptides encoded by APLN and APELA, respectively, which act on their receptor APJ and play crucial roles in the body. Recent research has shown that they not only have important effects on the endocrine system, but also promote vascular development and maintain the homeostasis of myocardial cells. From a molecular biology perspective, we explored the roles of Ela and apelin in the cardiovascular system and summarized the mechanisms of apelin-APJ signaling in the progression of myocardial infarction, ischemia-reperfusion injury, atherosclerosis, pulmonary arterial hypertension, preeclampsia, and congenital heart disease. Evidences indicated that apelin and Ela play important roles in cardiovascular diseases, and there are many studies focused on developing apelin, Ela, and their analogues for clinical treatments. However, the literature on the therapeutic potential of apelin, Ela and their analogues and other APJ agonists in the cardiovascular system is still limited. This review summarized the regulatory pathways of apelin/ELA-APJ axis in cardiovascular function and cardiovascular-related diseases, and the therapeutic effects of their analogues in cardiovascular diseases were also included.

Keywords: APJ; Apelin; Cardiovascular disease; Elabela; Therapy; Treatment.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no conflict of interest.

Similar articles

• ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.

  Sato T, Sato C, Kadowaki A, Watanabe H, Ho L, Ishida J, Yamaguchi T, Kimura A, Fukamizu A, Penninger JM, Reversade B, Ito H, Imai Y, Kuba K. Sato T, et al. Cardiovasc Res. 2017 Jun 1;113(7):760-769. doi: 10.1093/cvr/cvx061. Cardiovasc Res. 2017. PMID: 28371822

• Essential Role of the ELABELA-APJ Signaling Pathway in Cardiovascular System Development and Diseases.

  Zhou S, Wang J, Wang Q, Meng Z, Peng J, Song W, Zhou Y, Chen S, Chen F, Sun K. Zhou S, et al. J Cardiovasc Pharmacol. 2020 Apr;75(4):284-291. doi: 10.1097/FJC.0000000000000803. J Cardiovasc Pharmacol. 2020. PMID: 32000202 Review.

• The biological function of ELABELA and APJ signaling in the cardiovascular system and pre-eclampsia.

  Liu Y, Wang L, Shi H. Liu Y, et al. Hypertens Res. 2019 Jul;42(7):928-934. doi: 10.1038/s41440-018-0193-3. Epub 2019 Jan 9. Hypertens Res. 2019. PMID: 30626933 Review.

• Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension.

  Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell NW, Maguire JJ, Davenport AP. Yang P, et al. Circulation. 2017 Mar 21;135(12):1160-1173. doi: 10.1161/CIRCULATIONAHA.116.023218. Epub 2017 Jan 30. Circulation. 2017. PMID: 28137936 Free PMC article.

• The Elabela-APJ axis: a promising therapeutic target for heart failure.

  Ma Z, Song JJ, Martin S, Yang XC, Zhong JC. Ma Z, et al. Heart Fail Rev. 2021 Sep;26(5):1249-1258. doi: 10.1007/s10741-020-09957-5. Heart Fail Rev. 2021. PMID: 32314083 Free PMC article. Review.

Cited by

• Protective effect of apelin-13 on ventilator-induced acute lung injury.

  Lian S, Zhang X, Shen Y, He S, Chen Z, Zhou L, Jiang W. Lian S, et al. Mol Biol Rep. 2024 Jan 4;51(1):74. doi: 10.1007/s11033-023-08911-6. Mol Biol Rep. 2024. PMID: 38175266

• Apelin ameliorates sepsis-induced myocardial dysfunction via inhibition of NLRP3-mediated pyroptosis of cardiomyocytes.

  Cao Z, Li W, Shao Z, Liu X, Zeng Y, Lin P, Lin C, Zhao Y, Li T, Zhao Z, Li X, Zhang Y, Hu B. Cao Z, et al. Heliyon. 2024 Jan 23;10(3):e24568. doi: 10.1016/j.heliyon.2024.e24568. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38356599 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science